ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
125.661,89
0,00%
S&P 500
5.537,02
0,51%
US Dollar vs BRL
5,49356
-1,14%
Bitcoin
57.531,04
-4,37%
Brent Oil
86,705
-0,24%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Biomea Fusion Inc (BMEA)

  7. Biomea Fusion Inc (BMEA) Notícias

BMEA

Biomea Fusion (BMEA)

Biomea Fusion Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:BMEA
DataHoraFonteTítuloCódigoCompanhia
13/06/202417:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMEABiomea Fusion Inc
12/06/202418:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BMEABiomea Fusion Inc
06/06/202417:05GlobeNewswire Inc.Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical HoldNASDAQ:BMEABiomea Fusion Inc
03/06/202417:05GlobeNewswire Inc.Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BMEABiomea Fusion Inc
30/05/202410:12GlobeNewswire Inc.Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 DiabetesNASDAQ:BMEABiomea Fusion Inc
02/05/202417:05GlobeNewswire Inc.Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate HighlightsNASDAQ:BMEABiomea Fusion Inc
01/05/202417:10GlobeNewswire Inc.Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BMEABiomea Fusion Inc
01/04/202410:02GlobeNewswire Inc.Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219NASDAQ:BMEABiomea Fusion Inc
01/04/202410:00GlobeNewswire Inc.Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate HighlightsNASDAQ:BMEABiomea Fusion Inc
06/03/202405:04GlobeNewswire Inc.Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic FunctionNASDAQ:BMEABiomea Fusion Inc
01/03/202418:16GlobeNewswire Inc.Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BMEABiomea Fusion Inc
12/02/202419:00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:BMEABiomea Fusion Inc
09/01/202413:02GlobeNewswire Inc.Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:BMEABiomea Fusion Inc
08/01/202411:00GlobeNewswire Inc.Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219NASDAQ:BMEABiomea Fusion Inc
05/01/202418:02Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BMEABiomea Fusion Inc
02/01/202418:05GlobeNewswire Inc.Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:BMEABiomea Fusion Inc
11/12/202311:25GlobeNewswire Inc.Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASHNASDAQ:BMEABiomea Fusion Inc
09/12/202319:30GlobeNewswire Inc.Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose CohortsNASDAQ:BMEABiomea Fusion Inc
08/12/202311:00GlobeNewswire Inc.Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin ResistaNASDAQ:BMEABiomea Fusion Inc
07/12/202311:15GlobeNewswire Inc.Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular DiseNASDAQ:BMEABiomea Fusion Inc
05/12/202310:30GlobeNewswire Inc.Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 DiabetesNASDAQ:BMEABiomea Fusion Inc
27/11/202310:30GlobeNewswire Inc.Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024NASDAQ:BMEABiomea Fusion Inc
16/11/202310:30GlobeNewswire Inc.Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular DiseaseNASDAQ:BMEABiomea Fusion Inc
08/11/202318:05GlobeNewswire Inc.Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)NASDAQ:BMEABiomea Fusion Inc
02/11/202310:05GlobeNewswire Inc.Biomea Fusion Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023NASDAQ:BMEABiomea Fusion Inc
30/10/202317:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BMEABiomea Fusion Inc
30/10/202317:01GlobeNewswire Inc.Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate HighlightsNASDAQ:BMEABiomea Fusion Inc
17/10/202309:30GlobeNewswire Inc.Biomea Fusion Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)NASDAQ:BMEABiomea Fusion Inc
05/10/202309:30GlobeNewswire Inc.Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for BMF-219 in Type 1 DiabetesNASDAQ:BMEABiomea Fusion Inc
28/09/202309:30GlobeNewswire Inc.Biomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II StudyNASDAQ:BMEABiomea Fusion Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:BMEA

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
OIBR3
OI ON
BOV
COGN3
COGNA ON
BOV
PRIO3
PETRORIO ON
BOV
IRBR3
IRB BRASIL ON
BOV
HAGA3
HAGA ON
BOV
AGXY3
Agrogalaxy Participacoes ON
BOV
QUAL3
QUALICORP ON
BOV
BBFI11
BB Fundo Invest Imobilia...
BOV
AMAR3
LOJAS MARISA ON
BOV
MEAL3
IMC S/A ON
BOV
EUCA4
EUCATEX PN
BOV
GOLL4
GOL PN
BOV
IDIV
Dividend
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados